Healio Minute

In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more. Read the full coverage here: Lack of sunless tanner education may cause diagnostic confusion, UV exposure Intralesional HPV vaccine may clear recalcitrant warts New, positive results show Ilumetri imp...

In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more. Read the full coverage here: Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL CDC study reveals overall increase...

In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more. Read the full coverage here: Novel serum improves hair growth in androgenetic alopecia with no side effects Cardiovascular disease associated with four dermatological inflammatory dis...

In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies 'waiting' for patients with leukemia and more. Read the full coverage here: Seattle Children's pauses trial of CAR-T for leukemia after patient death Obesity may increase risk for blood cancer VIDEO: New CAR T-cell therapies 'waiting in the wings' for patients...

In this edition, Leqembi shows benefits in early Alzheimer's, sex before bed has more positive impact on sleep, clearer guidelines needed on melatonin use in children and more. Read the full coverage here: FDA committee says Leqembi shows benefits in early Alzheimer's Sex before bed has more positive impact on sleep vs. medication in adults with insomnia Increased education, clearer guidelines nee...

In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; 'new potential treatment option' for advanced chronic lymphocytic leukemia and more. Read the full coverage here: Prior authorization policies linked to 2-week delay in anticancer-drug prescription fills AYAs with rare leukemia face disparities in access to specialized canc...

In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more. Read the full coverage here: Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer First-line combination extends PFS in lung cancer subgroup...

In this edition, cross-border partnership takes on survival gap for children with leukemia; 'paradigm shift' in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis and more. Read the full coverage here: Cross-border partnership takes on 'huge survival gap' among children with leukemia Luspatercept 'a paradigm shift' in transfusion-dependent myelodysplastic syndrom...

In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer's and more. Read the full coverage here: FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment Leqemb...

In this edition, we bring you a deep dive on a collaboration that aims to accelerate better treatments for pediatric cancers. Read the full coverage here: Collaboration aims to 'truly accelerate better treatments' for pediatric cancers References: Dharia NV, et al.  Nat Med.  2021;doi:10.1038/s41588-021-00819-w.

In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more. Read the full coverage here: Tumor mutational burden may be linked to immunotherapy response in advanced cancers Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC Phase 3 study of lu...

In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more. Read the full coverage here: Addition of immunotherapy to chemotherapy improves survival rates of infants with leukemia Extreme poverty linked to nearly twofold higher risk for relapse among childr...

In this edition, trichloroethylene may be 'invisible' cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more. Read the full coverage here: Trichloroethylene may be 'invisible and highly preventable' cause of Parkinson's disease DEA petitioned to de-schedule dual orexin receptor antagonist insomnia medications Ravulizumab reduces clinical deterioration in...

In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for cancer drugs and more. Read the full coverage here: Black patients may be at elevated cardiotoxicity, HF risk after chemotherapy CV risk factor disparities in childhood cancer survivors similar to general...

In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more. Read the full coverage here: DNA sequencing could identify patients with AML at high risk for relapse after HSCT Review highlights major advances, continuing challenges in chronic lymphocytic leuk...

In this edition, 'paradigm shift' in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more. Read the full coverage here: Study reveals 'paradigm shift' in non-small cell lung cancer during past decade Osimertinib extends survival in early EGFR-mutated non-small cell lung...

In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Read the full coverage here: Optimal antibiotics timing 'likely differs' among inpatients with cancer, neutropenic fever Inflammation levels linked to survival in acute myeloid leuke...

In this edition, FDA clears lab blood test for evaluating concussion, marriage linked to lower risk for dementia, FDA approves nasal spray for migraine in adults and more. Read the full coverage here: FDA clears lab blood test for evaluating concussion Marriage linked to lower risk for dementia, mild cognitive impairment FDA approves nasal spray for migraine in adults Noninvasive device for treati...

In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage here: Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome Ponatinib 'should be considered a standard of care' for newly diagnosed Ph+ALL Iomab-B may increase transplant access, i...

In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more. Read the full coverage here: Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC Global economic cost of cancer estimated to exceed $25 trillion over 30 years Phase 3 trials of pembroli...

In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more. Read the full coverage here: Novel T-cell therapy effective against common viruses after stem cell transplantation FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma Review of...

In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Read the full coverage here: Lobectomy alternatives show varying adverse event profiles in early-stage lung cancer More frequent CT scans not linked to better outcomes after lung cancer surgery Osimertinib-related pneumonitis incide...

In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more. Read the full coverage here: Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer Atezolizumab-bevacizumab confers 'much higher than usual' survival rates in NSCLC subset Lung cancer s...

In this edition, groups support CMS policy update on colonoscopy; plant-based food intake and CRC research needed; FDA agrees on pediatric study to develop obefazimod and more. Read the full coverage here: Exact Sciences backs CMS policy update to waive cost-sharing for follow-up colonoscopy Future research needed to investigate link between plant-based food intake, CRC FDA agrees on Abivax's pedi...

In this edition, NCI director announces breast cancer diagnosis, neoadjuvant chemotherapy regimen in pancreatic cancer, gender harassment is in oncology and more. Read the full coverage here: NCI director announces breast cancer diagnosis, says prognosis 'very favorable' Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer Survey shows gender harassment is 'strikingly common' in...